0R3M Stock Chart & Stats
€1.17
€0.03(2.56%)
At close: 4:00 PM EDT
€1.17
€0.03(2.56%)
Day’s Range― - ―
52-Week Range€1.02 - €1.82
Previous CloseN/A
Volume7.00
Average Volume (3M)334.00
Market Cap
€33.17M
Enterprise Value€29.61
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume840
30 Day Avg. Volume334
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Alzheimer’s PipelineA clear, concentrated R&D focus on Alzheimer’s with an oral small‑molecule candidate (varoglutamstat/PQ912) supports a durable strategic thesis: fewer programs concentrate resources on a high‑value indication, oral chemistry can ease development/ commercialization complexity and enable broader patient access if successful.
Low Financial LeverageMinimal debt reduces refinancing and interest obligations, preserving operational flexibility over months. For a clinical‑stage biotech this lowers bankruptcy risk from leverage, enabling management to prioritize R&D progress or partnership negotiations rather than servicing debt.
Trend Toward Lower Cash BurnA meaningful reduction in operating cash outflow indicates management has slowed burn or optimized spend, extending runway and increasing the chance to reach clinical milestones or negotiate partnerships without immediate dilutive financing, a sustainably positive operational trend if maintained.
Bears Say
No Recent Revenue; Ongoing LossesAbsence of operating revenue and persistent net losses are structural constraints for the business model: until a product is commercialized or material licensing deals occur, the company must rely on external financing, limiting long‑term self‑sufficiency and increasing execution risk.
Sharply Eroded Equity And AssetsRapid depletion of equity and total assets materially reduces financial flexibility and the ability to absorb trial delays or setbacks. A much smaller balance sheet increases the likelihood of dilutive capital raises and constrains strategic options over the medium term.
Persistent Negative Cash Flow And Funding DependenceOngoing negative free cash flow creates a structural funding imperative: continued program progression requires external capital or partnerships. That dependence raises dilution and execution risk and could delay or disrupt development timelines if financing options weaken.
Vivoryon Therapeutics AG News
0R3M FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest share price was €1.02 and its highest was €1.82 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €33.17M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 109 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Vivoryon Therapeutics AG dividends here
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.966%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in GB:0R3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.